Please login to the form below

Not currently logged in
Email:
Password:

Kala names Howard Rosen as chairman

He is former CEO of Pearl Therapeutics and VP at Gilead
Howard Rosen, Kala

Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors.

Rosen has held several senior roles at major biotechs, including his current positions on the board of directors at AcelRX, Aldea, Entrega and PaxVax, where he is also chairman.

His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as a period as VP, commercial strategy at Gilead Sciences and president of Johnson & Johnson subsidiary ALZA Corporation.

Kala's president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.

“Howard's extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Pfefer, who joined the eyecare specialist from Sanofi in 2012.

8th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....